Summary

Ebola Virus Vaccine Market – Scope of Report
TMR’s report on the global Ebola virus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global Ebola virus vaccine market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Ebola virus vaccine market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Ebola virus vaccine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Ebola virus vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Ebola virus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Ebola virus vaccine market.

The report delves into the competitive landscape of the global Ebola virus vaccine market. Key players operating in the global Ebola virus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Ebola virus vaccine market profiled in this report.

Key Questions Answered in Global Ebola virus vaccine Market Report
• What is the sales/revenue generated by Ebola virus vaccine across all regions during the forecast period?
• What are the opportunities in the global Ebola virus vaccine market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Ebola Virus Vaccine Market – Research Objectives and Research Approach
The comprehensive report on the global Ebola virus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Ebola virus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Ebola virus vaccine market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ebola Virus Vaccine Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ebola Virus Vaccine Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Ebola Virus Vaccine Market Analysis and Forecast, by Vaccine Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine Type, 2020-2034
6.3.1. cAd3-ZEBOV
6.3.2. rVSV-ZEBOV
6.4. Market Attractiveness, by Vaccine Type
7. Global Ebola Virus Vaccine Market Analysis and Forecast, by Route of Administration
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2020-2034
7.3.1. Oral
7.3.2. Intravenous
7.4. Market Attractiveness, by Route of Administration
8. Global Ebola Virus Vaccine Market Analysis and Forecast, By Strain Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Strain Type, 2020-2034
8.3.1. Zaire
8.3.2. Sudan
8.3.3. Tai Forest
8.3.4. Reston
8.3.5. Bundibugyo Virus
8.4. Market Attractiveness, By Strain Type
9. Global Ebola Virus Vaccine Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Ebola Virus Vaccine Market Analysis and Forecast, by End-user
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2020-2034
10.3.1. Hospitals
10.3.2. Homecare
10.3.3. Specialty Clinics
10.3.4. Ambulatory Surgical Centers
10.3.5. Others (Outpatient Facilities, etc.)
10.4. Market Attractiveness, by End-user
11. Global Ebola Virus Vaccine Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2020-2034
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Ebola Virus Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vaccine Type, 2020-2034
12.2.1. CAd3-ZEBOV
12.2.2. RVSV-ZEBOV
12.3. Market Attractiveness, by Vaccine Type
12.4. Market Value Forecast, by Route of Administration, 2020-2034
12.4.1. Oral
12.4.2. Intravenous
12.5. Market Attractiveness, by Route of Administration
12.6. Market Value Forecast, By Strain Type, 2020-2034
12.6.1. Zaire
12.6.2. Sudan
12.6.3. Tai Forest
12.6.4. Reston
12.6.5. Bundibugyo Virus
12.7. Market Attractiveness, By Strain Type
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by End-user, 2020-2034
12.10.1. Hospitals
12.10.2. Homecare
12.10.3. Specialty Clinics
12.10.4. Ambulatory Surgical Centers
12.10.5. Others (Outpatient Facilities, etc.)
12.11. Market Attractiveness, by End-user
12.12. Market Value Forecast, by Country/Sub-region, 2020-2034
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Vaccine Type
12.13.2. By Route of Administration
12.13.3. By Strain Type
12.13.4. By Distribution Channel
12.13.5. By End-user
12.13.6. By Country
13. Europe Ebola Virus Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vaccine Type, 2020-2034
13.2.1. CAd3-ZEBOV
13.2.2. RVSV-ZEBOV
13.3. Market Attractiveness, by Vaccine Type
13.4. Market Value Forecast, by Route of Administration, 2020-2034
13.4.1. Oral
13.4.2. Intravenous
13.5. Market Attractiveness, by Route of Administration
13.6. Market Value Forecast, By Strain Type, 2020-2034
13.6.1. Zaire
13.6.2. Sudan
13.6.3. Tai Forest
13.6.4. Reston
13.6.5. Bundibugyo Virus
13.7. Market Attractiveness, By Strain Type
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by End-user, 2020-2034
13.10.1. Hospitals
13.10.2. Homecare
13.10.3. Specialty Clinics
13.10.4. Ambulatory Surgical Centers
13.10.5. Others (Outpatient Facilities, etc.)
13.11. Market Attractiveness, by End-user
13.12. Market Value Forecast, by Country/Sub-region, 2020-2034
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Vaccine Type
13.13.2. By Route of Administration
13.13.3. By Strain Type
13.13.4. By Distribution Channel
13.13.5. By End-user
13.13.6. By Country/Sub-region
14. Asia Pacific Ebola Virus Vaccine Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vaccine Type, 2020-2034
14.2.1. CAd3-ZEBOV
14.2.2. RVSV-ZEBOV
14.3. Market Attractiveness, by Vaccine Type
14.4. Market Value Forecast, by Route of Administration, 2020-2034
14.4.1. Oral
14.4.2. Intravenous
14.5. Market Attractiveness, by Route of Administration
14.6. Market Value Forecast, By Strain Type, 2020-2034
14.6.1. Zaire
14.6.2. Sudan
14.6.3. Tai Forest
14.6.4. Reston
14.6.5. Bundibugyo Virus
14.7. Market Attractiveness, By Strain Type
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by End-user, 2020-2034
14.10.1. Hospitals
14.10.2. Homecare
14.10.3. Specialty Clinics
14.10.4. Ambulatory Surgical Centers
14.10.5. Others (Outpatient Facilities, etc.)
14.11. Market Attractiveness, by End-user
14.12. Market Value Forecast, by Country/Sub-region, 2020-2034
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Vaccine Type
14.13.2. By Route of Administration
14.13.3. By Strain Type
14.13.4. By Distribution Channel
14.13.5. By End-user
14.13.6. By Country/Sub-region
15. Latin America Ebola Virus Vaccine Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Vaccine Type, 2020-2034
15.2.1. CAd3-ZEBOV
15.2.2. RVSV-ZEBOV
15.3. Market Attractiveness, by Vaccine Type
15.4. Market Value Forecast, by Route of Administration, 2020-2034
15.4.1. Oral
15.4.2. Intravenous
15.5. Market Attractiveness, by Route of Administration
15.6. Market Value Forecast, By Strain Type, 2020-2034
15.6.1. Zaire
15.6.2. Sudan
15.6.3. Tai Forest
15.6.4. Reston
15.6.5. Bundibugyo Virus
15.7. Market Attractiveness, By Strain Type
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by End-user, 2020-2034
15.10.1. Hospitals
15.10.2. Homecare
15.10.3. Specialty Clinics
15.10.4. Ambulatory Surgical Centers
15.10.5. Others (Outpatient Facilities, etc.)
15.11. Market Attractiveness, by End-user
15.12. Market Value Forecast, by Country/Sub-region, 2020-2034
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Vaccine Type
15.13.2. By Route of Administration
15.13.3. By Strain Type
15.13.4. By Distribution Channel
15.13.5. By End-user
15.13.6. By Country/Sub-region
16. Middle East & Africa Ebola Virus Vaccine Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Vaccine Type, 2020-2034
16.2.1. CAd3-ZEBOV
16.2.2. RVSV-ZEBOV
16.3. Market Attractiveness, by Vaccine Type
16.4. Market Value Forecast, by Route of Administration, 2020-2034
16.4.1. Oral
16.4.2. Intravenous
16.5. Market Attractiveness, by Route of Administration
16.6. Market Value Forecast, By Strain Type, 2020-2034
16.6.1. Zaire
16.6.2. Sudan
16.6.3. Tai Forest
16.6.4. Reston
16.6.5. Bundibugyo Virus
16.7. Market Attractiveness, By Strain Type
16.8. Market Value Forecast, by Distribution Channel, 2020-2034
16.8.1. Hospital Pharmacies
16.8.2. Retail Pharmacies
16.8.3. Online Pharmacies
16.9. Market Attractiveness, by Distribution Channel
16.10. Market Value Forecast, by End-user, 2020-2034
16.10.1. Hospitals
16.10.2. Homecare
16.10.3. Specialty Clinics
16.10.4. Ambulatory Surgical Centers
16.10.5. Others (Outpatient Facilities, etc.)
16.11. Market Attractiveness, by End-user
16.12. Market Value Forecast, by Country/Sub-region, 2020-2034
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Vaccine Type
16.13.2. By Route of Administration
16.13.3. By Strain Type
16.13.4. By Distribution Channel
16.13.5. By End-user
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2023)
17.3. Company Profiles
17.3.1. Arbutus Biopharma Corporation
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. GSK plc
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Johnson & Johnson Services, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. AIM ImmunoTech Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. BioCryst Pharmaceuticals
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. NanoViricides, Inc.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. NewLink Genetics Corporation
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Chimerix, Inc.
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Sarepta Therapeutics, Inc.
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Mapp Biopharmaceutical, Inc.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview